EU/3/19/2170: Orphan designation for the treatment of beta thalassaemia intermedia and major

2-(2-{[2-(1H-benzimidazol-2-yl)ethyl]amino}ethyl)-N-[(3-fluoropyridine-2-yl)methyl]-1,3-oxazole-4-carboxamide trihydrochloride

Table of contents


On 28 June 2019, orphan designation EU/3/19/2170 was granted by the European Commission to Vifor France S.A., France, for 2-(2-{[2-(1H-benzimidazol-2-yl)ethyl]amino}ethyl)-N-[(3-fluoropyridin-2-yl)methyl]-1,3-oxazole-4-carboxamide trihydrochloride (also known as VIT-2763) for the treatment of beta-thalassaemia intermedia and major.

Key facts

Active substance
2-(2-{[2-(1H-benzimidazol-2-yl)ethyl]amino}ethyl)-N-[(3-fluoropyridine-2-yl)methyl]-1,3-oxazole-4-carboxamide trihydrochloride
Intended use
Treatment of beta thalassaemia intermedia and major
Orphan designation status
EU designation number
Date of designation

Vifor France S.A.
Tour Franklin La Defense 8
100-101 Terrasse Boieldieu
92042 Paris La Defense Cedex
Tel. +33 1410 65890; +41 5885 18000 (Switzerland)

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating